Roche Holding AG is willing to pay more than $1 billion to solve one of the biggest challenges of gene therapy: delivery.The ...
After forming a gene therapy partnership with Dyno Therapeutics in 2020, Roche is back for more. | In a new deal potentially ...
With an upfront payment of $50 million from Roche, the partnership will leverage Dyno Therapeutics’ in vivo gene therapy ...
GlobalData on MSN22h
Dyno and Roche collaborate on neurological gene therapiesDyno Therapeutics has formed a new research partnership with Roche, focusing on the development of next-generation ...
Roche will use Dyno’s technology, through which Dyno applies AI and high-throughput in vivo data collection to engineering ...
By squeezing Regeneron’s Eylea, eye disease drug Vabysmo has become one of the biggest growth drivers for Roche. | Despite ...
George Church-founded Dyno Therapeutics Inc. is adding to its list of pharma deals by signing a second research collaboration ...
US artificial intelligence (AI) to gene therapy focussed biotech Dyno Therapeutics today announced its second research ...
Existing gene therapies have primarily used a small number of naturally occurring AAV vectors limited by low delivery efficiency as well as problems with pre-existing immunity and manufacturability.
GlobalData on MSN2d
Be Bio raises $82m to advance haemophilia B gene therapy to Phase I/II trialBe Biopharma has raised $82m in financing to advance a gene therapy targeting hemophilia B to a Phase I/II trial, whilst also ...
Last week, U.S. consumer groups and labour unions petitioned the U.S. Federal Trade Commission to block Novo Holdings, the ...
About 500 children worldwide have received the gene therapy, including some families traveling abroad to gain access to it.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback